Cresemba 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended on 
IB/0040/G 
This was an application for a group of variations. 
19/12/2022 
SmPC, Annex II 
and PL 
B.II.a.z - Change in description and composition of the 
Finished Product - Other variation 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
responsible for importation and/or batch release - Not 
including batch control/testing 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
IA/0039 
B.II.b.5.b - Change to in-process tests or limits 
19/09/2022 
n/a 
applied during the manufacture of the finished product 
- Addition of a new test(s) and limits 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
22/04/2022 
21/06/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds 
/202109 
isavuconazole 
recommending the variation to terms of the Marketing 
Authorisation(s)’ for PSUSA/10426/202109. 
IB/0038 
B.I.b.2.e - Change in test procedure for AS or starting 
07/01/2022 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
II/0036 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
28/10/2021 
19/05/2022 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0035/G 
This was an application for a group of variations. 
08/07/2021 
n/a 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0034 
B.I.a.2.z - Changes in the manufacturing process of 
11/06/2021 
n/a 
the AS - Other variation 
II/0030 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
22/04/2021 
19/05/2022 
SmPC, Labelling 
new quality, preclinical, clinical or pharmacovigilance 
and PL 
data 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
/202009 
isavuconazole 
II/0031 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
28/01/2021 
19/05/2022 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
IA/0032/G 
This was an application for a group of variations. 
11/09/2020 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold increase 
compared to the originally approved batch size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold increase 
compared to the originally approved batch size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold increase 
compared to the originally approved batch size 
R/0027 
Renewal of the marketing authorisation. 
28/05/2020 
13/08/2020 
SmPC, Annex II, 
Based on the review of data on quality, safety and 
Labelling and PL 
efficacy, the CHMP considered that the benefit-risk 
balance of Cresemba in the approved indications 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
17/04/2020 
n/a 
PRAC Recommendation - maintenance 
/201909 
isavuconazole 
validity. 
IB/0029 
B.I.a.1.z - Change in the manufacturer of AS or of a 
06/03/2020 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
N/0026 
Minor change in labelling or package leaflet not 
08/01/2020 
23/04/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
03/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201903 
isavuconazole 
II/0024/G 
This was an application for a group of variations. 
26/09/2019 
23/04/2020 
SmPC, Labelling 
and PL 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change outside 
the approved specifications limits range 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IA/0023/G 
This was an application for a group of variations. 
07/08/2019 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold increase 
compared to the originally approved batch size 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.c.1.a - Change in immediate packaging of the AS - 
Qualitative and/or quantitative composition 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
11/04/2019 
n/a 
PRAC Recommendation - maintenance 
/201809 
isavuconazole 
IAIN/0021/G 
This was an application for a group of variations. 
04/04/2019 
23/04/2020 
Annex II and PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
T/0020 
Transfer of Marketing Authorisation 
08/02/2019 
11/03/2019 
SmPC, Labelling 
and PL 
IAIN/0019 
A.1 - Administrative change - Change in the name 
06/02/2019 
11/03/2019 
SmPC, Labelling 
and/or address of the MAH 
and PL 
IA/0018/G 
This was an application for a group of variations. 
19/12/2018 
n/a 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
N/0017 
Minor change in labelling or package leaflet not 
13/12/2018 
11/03/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/11/2018 
11/03/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
04/10/2018 
n/a 
PRAC Recommendation - maintenance 
/201803 
isavuconazole 
IB/0013 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf life 
30/08/2018 
11/03/2019 
SmPC 
of the finished product - As packaged for sale 
(supported by real time data) 
IA/0014 
A.7 - Administrative change - Deletion of 
14/08/2018 
n/a 
manufacturing sites 
IA/0012/G 
This was an application for a group of variations. 
18/07/2018 
n/a 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
12/04/2018 
n/a 
PRAC Recommendation - maintenance 
/201709 
isavuconazole 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0010 
B.I.a.4.c - Change to in-process tests or limits applied 
04/04/2018 
n/a 
during the manufacture of the AS - Deletion of a 
non-significant in-process test 
IB/0009 
B.I.b.2.e - Change in test procedure for AS or starting 
04/04/2018 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
IB/0008 
B.I.b.2.e - Change in test procedure for AS or starting 
04/04/2018 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201703 
isavuconazole 
N/0006 
Minor change in labelling or package leaflet not 
24/08/2017 
30/01/2018 
Labelling and PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0005/G 
This was an application for a group of variations. 
18/07/2017 
n/a 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
B.I.a.4.a - Change to in-process tests or limits applied 
during the manufacture of the AS - Tightening of 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in-process limits 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
06/04/2017 
n/a 
PRAC Recommendation - maintenance 
/201609 
isavuconazole 
IB/0002 
C.I.z - Changes (Safety/Efficacy) of Human and 
13/01/2017 
30/01/2018 
SmPC 
MAH was requested to submit the summaries of two 
Veterinary Medicinal Products - Other variation 
new studies which are updating the Environmental Risk 
Assessment Report.  
The Rapporteur conclusions state that Cresemba may 
pose a risk for the aquatic environment therefore 
updates to sections 5.3 and 6.6 of the current SmPC are 
recommended. 
PSUSA/10426
Periodic Safety Update EU Single assessment - 
29/09/2016 
n/a 
PRAC Recommendation - maintenance 
/201603 
isavuconazole 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
